CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

@article{Tirelli1998CHOPIT,
  title={CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.},
  author={Umberto Tirelli and Domenico Errante and M van Glabbeke and Ivana Teodorovic and Johanna C Kluin-Nelemans and J. -P. Thomas and Dominique Bron and Giovanni Rosti and Robert Somers and Vittorina Zagonel and E. M. Noordijk},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 1},
  pages={27-34}
}
PURPOSE We report the results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group, which compared a chemotherapy regimen specifically devised for elderly patients, ie, etoposide, mitoxantrone, and prednimustine (VMP), versus the standard regimen of cyclophosphamide, doxorobucin, vincristine, and prednisone (CHOP) in patients older than 70 years of age with intermediate- and high-grade non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 55 extracted citations

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper.

Annals of oncology : official journal of the European Society for Medical Oncology • 2011
View 14 Excerpts
Highly Influenced

Oral Etoposide in Lymphoma

Drugs • 1999
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…